Authors:
TE Hickey, JLL Robinson, JS Carroll, WD Tilley
Journal name: 
Mol Endocrinol
Citation info: 
26(8):1252-1267
Abstract: 
Androgen receptor (AR) signaling exerts an antiestrogenic, growth-inhibitory influence in normal breast tissue, and this role may be sustained in estrogen receptor α (ERα)-positive luminal breast cancers. Conversely, AR signaling may promote growth of a subset of ERα-negative, AR-positive breast cancers with a molecular apocrine phenotype. Understanding the molecular mechanisms whereby androgens can elicit distinct gene expression programs and opposing proliferative responses in these two breast cancer phenotypes is critical to the development of new therapeutic strategies to target the AR in breast cancer.
DOI: 
http://doi.org/10.1210/me.2012-1107
Research group: 
Carroll Group
E-pub date: 
31 Aug 2012